Erythropoietin (EPO) (EPO)

FDA Approved

EPO | Red Blood Cell Stimulating Hormone

Weight: 30,400 Da
Half-life: 4-12 hours (IV), ~25 hours (SubQ)
Chain: 165 amino acids
4 studies
2024 latest
Extensively Studied
Dose 50-300 IU/kg based on medical indication
Frequency 1-3 times weekly depending on response
Cycle Variable - ongoing medical therapy adjusted based on hemoglobin levels
Storage 2-8°C refrigerated; do not freeze; do not shake vials or syringes
Accumulation Plotter

Community Research

Join others researching Erythropoietin (EPO) — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Erythropoietin (EPO) is an essential glycoprotein hormone that stimulates red blood cell production. Naturally produced by the kidneys in response to low oxygen levels, recombinant human EPO is FDA-approved for treating anemia in chronic kidney disease and chemotherapy patients. EPO binding to receptors on bone marrow cells promotes survival and maturation of red blood cell precursors, increasing oxygen-carrying capacity. Due to performance-enhancing effects, it is banned in competitive sports.

Mechanism of Action

EPO binds to erythropoietin receptors (EPOR) on erythroid progenitor cells in bone marrow, activating three interconnected signaling pathways: JAK2/STAT5, PI3K/AKT, and RAS/MAPK. This promotes survival of red blood cell precursors by protecting them from apoptosis, accelerates proliferation and differentiation of erythroid cells, and increases hemoglobin production. Under hypoxic stress, endogenous EPO production can increase up to 1000-fold, demonstrating the body's powerful oxygen-sensing regulatory system.

01 Stimulates red blood cell production
02 Increases oxygen-carrying capacity
03 FDA-approved for anemia treatment
04 Improves endurance capacity
05 Supports patients with chronic kidney disease
06 Helps chemotherapy-induced anemia
07 Well-characterized mechanism of action
08 Extensively studied safety profile

Molecular Data

Molecular Weight
30,400 Da
Chain Length
165 amino acids
Type
Glycoprotein hormone
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Medical Indications (FDA-Approved)
CKD-Related Anemia most effective

Primary FDA-approved indication for anemia secondary to chronic kidney disease.

Chemotherapy-Induced Anemia most effective

FDA-approved for treating anemia in cancer patients receiving chemotherapy.

Surgical Blood Loss effective

Used to reduce need for blood transfusions in certain surgical settings.

Performance (Banned in Sports)
Endurance Enhancement most effective

Increases oxygen delivery to muscles, improving endurance capacity. Banned by WADA.

Altitude Acclimatization effective

May accelerate adaptation to high altitude by increasing red blood cell mass.

Dosing Protocols

EPO is administered via subcutaneous or intravenous injection. Medical use requires prescription and monitoring. Dosing is individualized based on hemoglobin levels, with targets typically kept below 11-12 g/dL to minimize cardiovascular risks.

GoalDoseFrequencyRoute
CKD Anemia (medical)50-100 IU/kg3x weeklySubQ or IV
Chemotherapy Anemia (medical)150-300 IU/kg3x weeklySubQ
Maintenance (medical)Individualized1-3x weeklySubQ

Reconstitution Instructions

Materials Needed:
  • Pre-filled syringes (most common)
  • Or lyophilized powder with diluent
  • Alcohol swabs
  • Cold storage
  1. 1 Most EPO comes in pre-filled syringes
  2. 2 Allow to reach room temperature before injection
  3. 3 Inject subcutaneously or intravenously as directed
  4. 4 Do not shake vials or syringes

Interactions

++
Iron supplementation
Iron is essential for hemoglobin production; often co-administered with EPO therapy.
synergistic
+
TB-500
Different mechanisms; no known interactions.
compatible
+
BPC-157
Different mechanisms; no known interactions.
compatible

What to Expect

Days 1-3
Bone marrow stimulation begins
Week 1-2
Reticulocyte count increases
Week 2-4
Hemoglobin begins rising
Week 4-12
Target hemoglobin achieved with proper dosing

Side Effects & Safety

Common Side Effects

  • Injection site reactions
  • Headache
  • Hypertension
  • Joint pain
  • Flu-like symptoms

Stop Signs - Discontinue if:

  • Severe headache or vision changes
  • Chest pain or shortness of breath
  • Signs of blood clots (leg swelling, pain)
  • Sudden loss of response to EPO

Contraindications

  • Uncontrolled hypertension
  • Pure red cell aplasia history
  • Hemoglobin >12 g/dL (increased cardiovascular risk)
  • Active malignancy (relative contraindication)

Quality Checklist

Good Signs

  • Clear, colorless solution
  • Pharmaceutical grade product
  • Proper cold chain maintained
  • Intact packaging and seals

Warning Signs

  • Research-grade products lack quality assurance
  • Temperature excursions may affect potency

Bad Signs

  • Cloudy or discolored solution
  • Particulates visible
  • Exposed to room temperature

References

  • Erythropoietin regulation of red blood cell production
    PMC/NCBI (2020)

    Comprehensive review of EPO's oxygen-sensing mechanism and regulation of RBC production.

  • Erythropoietin Stimulating Agents
    StatPearls (NCBI Bookshelf) (2024)

    FDA-approved indications include CKD anemia and chemotherapy-induced anemia. Risks increase when hemoglobin exceeds 11-12 g/dL.

  • Erythropoiesis-stimulating agents and other methods to enhance oxygen transport
    PMC (2008)

    rHuEPO increases O2 supply to muscles and boosts performance in endurance sports.

  • The mechanism of erythropoietin action
    PubMed (1992)

    EPO promotes survival of erythroid progenitors by protecting from apoptosis.

Related Peptides

TB-500 compatible

Different mechanisms; no known interactions.

BPC-157 compatible

Different mechanisms; no known interactions.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.